{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/15318"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/15318","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"CHEMO-PREVENTATIVE EFFECTS OF HYDROGEN SULFIDE-RELEASING NSAIDS IN MURINE COLORECTAL CANCER","abstract":"<p>Colorectal cancer leads to more than 600,000 deaths worldwide per year. An abundance of research has shown that several non-steroidal anti-inflammatory drugs (NSAIDs) can exert chemotherapeutic and chemo-preventative effects in colorectal cancer patients. It is important to note, that use of many different NSAIDs carries a significant risk for cardiovascular and gastrointestinal (GI) complications. A recently developed group of NSAIDs, which release hydrogen sulfide (H<sub>2</sub>S), has been shown to have greatly reduced these side effects as compared to conventional NSAIDs. This is likely attributable to the ability of H<sub>2</sub>S to increase the resistance of the GI mucosa to injury, as well as to accelerate repair of injury when it occurs. Moreover, H<sub>2</sub>S has been shown to be a vasodilator, and therefore may offset some of the hypertensive effects of NSAIDs.</p> <p>We assessed the chemotherapeutic actions of two of these newly developed NSAIDs. ATB-346 is an H<sub>2</sub>S-releasing derivative of naproxen and ATB-352 is an H<sub>2</sub>S-releasing derivative of ketoprofen. These drugs were tested in the azoxymethane mouse model and in the APC<sup>Min/+ </sup>mouse model of Colorectal cancer.</p> <p>In the azoxymethane model of colorectal cancer ATB-346 caused a significant reduction in number aberrant crypt foci (ACF), which are pre-neoplastic lesions used as markers of colorectal cancer. The reduction was superior to naproxen at all doses tested. ATB-352 also caused a significant reduction in the number of ACF, however the reduction was not superior to that produced by ketoprofen. In APC<sup>Min/+ </sup>mice treated with ATB-346 for 14 days (14.5 mg/kg) we observed a complete inhibition of the formation of colonic polyps/tumours and a 97.5% reduction in total polyp score. Shorter treatment with ATB-346 also produced similar reduction in total polyp score. We found that ATB-346-treated mice had lower levels of b-catenin and cmyc without significant changes in APC or p53 levels. <strong></strong></p> <p>These results demonstrate ATB-346 can exert superior chemo-preventative effects in mice models of colon cancer while leading to no gastric or intestinal damage.</p>","abstract_html":"&lt;p&gt;Colorectal cancer leads to more than 600,000 deaths worldwide per year. An abundance of research has shown that several non-steroidal anti-inflammatory drugs (NSAIDs) can exert chemotherapeutic and chemo-preventative effects in colorectal cancer patients. It is important to note, that use of many different NSAIDs carries a significant risk for cardiovascular and gastrointestinal (GI) complications. A recently developed group of NSAIDs, which release hydrogen sulfide (H&lt;sub&gt;2&lt;/sub&gt;S), has been shown to have greatly reduced these side effects as compared to conventional NSAIDs. This is likely attributable to the ability of H&lt;sub&gt;2&lt;/sub&gt;S to increase the resistance of the GI mucosa to injury, as well as to accelerate repair of injury when it occurs. Moreover, H&lt;sub&gt;2&lt;/sub&gt;S has been shown to be a vasodilator, and therefore may offset some of the hypertensive effects of NSAIDs.&lt;/p&gt; &lt;p&gt;We assessed the chemotherapeutic actions of two of these newly developed NSAIDs. ATB-346 is an H&lt;sub&gt;2&lt;/sub&gt;S-releasing derivative of naproxen and ATB-352 is an H&lt;sub&gt;2&lt;/sub&gt;S-releasing derivative of ketoprofen. These drugs were tested in the azoxymethane mouse model and in the APC&lt;sup&gt;Min/+ &lt;/sup&gt;mouse model of Colorectal cancer.&lt;/p&gt; &lt;p&gt;In the azoxymethane model of colorectal cancer ATB-346 caused a significant reduction in number aberrant crypt foci (ACF), which are pre-neoplastic lesions used as markers of colorectal cancer. The reduction was superior to naproxen at all doses tested. ATB-352 also caused a significant reduction in the number of ACF, however the reduction was not superior to that produced by ketoprofen. In APC&lt;sup&gt;Min/+ &lt;/sup&gt;mice treated with ATB-346 for 14 days (14.5 mg/kg) we observed a complete inhibition of the formation of colonic polyps/tumours and a 97.5% reduction in total polyp score. Shorter treatment with ATB-346 also produced similar reduction in total polyp score. We found that ATB-346-treated mice had lower levels of b-catenin and cmyc without significant changes in APC or p53 levels. &lt;strong&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;These results demonstrate ATB-346 can exert superior chemo-preventative effects in mice models of colon cancer while leading to no gastric or intestinal damage.&lt;/p&gt;","abstract_has_math":false,"creators":["Elsheikh, Wagdi K."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Division of Physiology/Pharmacology)","school":null,"contributors":[],"advisors":["Wallace, John L."],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-04","date_published":"2014-04","updated_at":"2026-11-19T05:55:01Z","subjects":["Colorectal Cancer","NSAIDs","Neoplasms","Gastrointestinal Disease","Chemo-prevention","Hydrogen Sulfide","Digestive System Diseases","Medical Pharmacology","Pharmaceutics and Drug Design"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/18289"],"render_values":[{"text":"https://doi.org/10.71548/18289","href":"https://doi.org/10.71548/18289","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8628","9704","4925588"],"render_values":[{"text":"opendissertations/8628","href":null,"code":true},{"text":"9704","href":null,"code":true},{"text":"4925588","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/15318","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/15318","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":"embargoed","embargo_until":"2014-12-12","access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F15318","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Wallace, John L."]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Division of Physiology/Pharmacology)"]},{"key":"dc:creator","label":"Author","values":["Elsheikh, Wagdi K."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T21:13:37Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-12-15"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2014-12-12"]},{"key":"dc:date.issued","label":"Date","values":["2014-04"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Colorectal Cancer","NSAIDs","Neoplasms","Gastrointestinal Disease","Chemo-prevention","Hydrogen Sulfide","Digestive System Diseases","Medical Pharmacology","Pharmaceutics and Drug Design"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8628","9704","4925588"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/15318","https://doi.org/10.71548/18289"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Colorectal cancer leads to more than 600,000 deaths worldwide per year. An abundance of research has shown that several non-steroidal anti-inflammatory drugs (NSAIDs) can exert chemotherapeutic and chemo-preventative effects in colorectal cancer patients. It is important to note, that use of many different NSAIDs carries a significant risk for cardiovascular and gastrointestinal (GI) complications. A recently developed group of NSAIDs, which release hydrogen sulfide (H<sub>2</sub>S), has been shown to have greatly reduced these side effects as compared to conventional NSAIDs. This is likely attributable to the ability of H<sub>2</sub>S to increase the resistance of the GI mucosa to injury, as well as to accelerate repair of injury when it occurs. Moreover, H<sub>2</sub>S has been shown to be a vasodilator, and therefore may offset some of the hypertensive effects of NSAIDs.</p> <p>We assessed the chemotherapeutic actions of two of these newly developed NSAIDs. ATB-346 is an H<sub>2</sub>S-releasing derivative of naproxen and ATB-352 is an H<sub>2</sub>S-releasing derivative of ketoprofen. These drugs were tested in the azoxymethane mouse model and in the APC<sup>Min/+ </sup>mouse model of Colorectal cancer.</p> <p>In the azoxymethane model of colorectal cancer ATB-346 caused a significant reduction in number aberrant crypt foci (ACF), which are pre-neoplastic lesions used as markers of colorectal cancer. The reduction was superior to naproxen at all doses tested. ATB-352 also caused a significant reduction in the number of ACF, however the reduction was not superior to that produced by ketoprofen. In APC<sup>Min/+ </sup>mice treated with ATB-346 for 14 days (14.5 mg/kg) we observed a complete inhibition of the formation of colonic polyps/tumours and a 97.5% reduction in total polyp score. Shorter treatment with ATB-346 also produced similar reduction in total polyp score. We found that ATB-346-treated mice had lower levels of b-catenin and cmyc without significant changes in APC or p53 levels. <strong></strong></p> <p>These results demonstrate ATB-346 can exert superior chemo-preventative effects in mice models of colon cancer while leading to no gastric or intestinal damage.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["CHEMO-PREVENTATIVE EFFECTS OF HYDROGEN SULFIDE-RELEASING NSAIDS IN MURINE COLORECTAL CANCER"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Wallace, John L."],"dc:contributor.department":["Medical Sciences (Division of Physiology/Pharmacology)"],"dc:creator":["Elsheikh, Wagdi K."],"dc:date.accessioned":["2014-06-18T21:13:37Z"],"dc:date.created":["2013-12-15"],"dc:date.embargo":["2014-12-12"],"dc:date.issued":["2014-04"],"dc:description.abstract":["<p>Colorectal cancer leads to more than 600,000 deaths worldwide per year. An abundance of research has shown that several non-steroidal anti-inflammatory drugs (NSAIDs) can exert chemotherapeutic and chemo-preventative effects in colorectal cancer patients. It is important to note, that use of many different NSAIDs carries a significant risk for cardiovascular and gastrointestinal (GI) complications. A recently developed group of NSAIDs, which release hydrogen sulfide (H<sub>2</sub>S), has been shown to have greatly reduced these side effects as compared to conventional NSAIDs. This is likely attributable to the ability of H<sub>2</sub>S to increase the resistance of the GI mucosa to injury, as well as to accelerate repair of injury when it occurs. Moreover, H<sub>2</sub>S has been shown to be a vasodilator, and therefore may offset some of the hypertensive effects of NSAIDs.</p> <p>We assessed the chemotherapeutic actions of two of these newly developed NSAIDs. ATB-346 is an H<sub>2</sub>S-releasing derivative of naproxen and ATB-352 is an H<sub>2</sub>S-releasing derivative of ketoprofen. These drugs were tested in the azoxymethane mouse model and in the APC<sup>Min/+ </sup>mouse model of Colorectal cancer.</p> <p>In the azoxymethane model of colorectal cancer ATB-346 caused a significant reduction in number aberrant crypt foci (ACF), which are pre-neoplastic lesions used as markers of colorectal cancer. The reduction was superior to naproxen at all doses tested. ATB-352 also caused a significant reduction in the number of ACF, however the reduction was not superior to that produced by ketoprofen. In APC<sup>Min/+ </sup>mice treated with ATB-346 for 14 days (14.5 mg/kg) we observed a complete inhibition of the formation of colonic polyps/tumours and a 97.5% reduction in total polyp score. Shorter treatment with ATB-346 also produced similar reduction in total polyp score. We found that ATB-346-treated mice had lower levels of b-catenin and cmyc without significant changes in APC or p53 levels. <strong></strong></p> <p>These results demonstrate ATB-346 can exert superior chemo-preventative effects in mice models of colon cancer while leading to no gastric or intestinal damage.</p>"],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.other":["opendissertations/8628","9704","4925588"],"dc:identifier.uri":["http://hdl.handle.net/11375/15318","https://doi.org/10.71548/18289"],"dc:subject":["Colorectal Cancer","NSAIDs","Neoplasms","Gastrointestinal Disease","Chemo-prevention","Hydrogen Sulfide","Digestive System Diseases","Medical Pharmacology","Pharmaceutics and Drug Design"],"dc:title":["CHEMO-PREVENTATIVE EFFECTS OF HYDROGEN SULFIDE-RELEASING NSAIDS IN MURINE COLORECTAL CANCER"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-19T05:55:01Z"}